ADCT – adc therapeutics sa common shares (US:NASDAQ)
Stock Stats
News
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma [Yahoo! Finance]
ADC Therapeutics (NYSE:ADCT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript [Seeking Alpha]
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma [Yahoo! Finance
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Form SCHEDULE 13G/A ADC Therapeutics SA Filed by: Prosight Management, LP
Form S-3 ADC Therapeutics SA
Form 10-Q ADC Therapeutics SA For: Sep 30
Form 8-K ADC Therapeutics SA For: Nov 10
Form SCHEDULE 13G/A ADC Therapeutics SA Filed by: Oaktree Capital Group Holdings GP, LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.